Navigating the Challenging Landscape of NASH Therapeutics| Rohan Palekar, CEO, 89bio Inc. 00:10:00
89bio CEO Rohan Palekar provides an insider's perspective on the hurdles facing the non-alcoholic steatohepatitis (NASH) therapeutics market, highlighting challenges such as FDA approval processes, clinical trial design issues, and investor caution, while expressing optimism for breakthroughs through safety, convenience, and innovative testing technology.